|
|
|
市場調查報告書
全球癌症疫苗市場（第2版）：產品線分析及未來市場影響
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact
|
全球癌症疫苗市場（第2版）：產品線分析及未來市場影響 是由出版商Arrowhead Publishers在2011年01月所出版的。
這份英文市場調查報告書價格從美金2750起跳。
本報告為，分析治療用癌症疫苗之研發趨勢、臨床實驗標準及第3相疫苗候補之臨床性、商業分析、意見領袖於癌症治療之疫苗接受度、2020年止成長率等，以下列摘要形式闡述。
第1章 實施概要
第2章 癌症流行病學及經濟性影響
第3章 治療用癌症疫苗簡介
- 免疫系統及癌症
- 何謂疫苗
- 目前癌症治療之未滿足需求
- 癌症疫苗之基本資訊
- 為何使用治療用癌症疫苗
- 初期致力癌症疫苗發展
- 異體及自體疫苗
- 癌症疫苗種類
第4章 疫苗及結直腸癌治療市場
第5章 疫苗及前列腺癌治療市場
第6章 疫苗及肺癌治療市場
第7章 疫苗及乳癌治療市場
第8章 疫苗及胰臟癌治療市場
第9章 疫苗黑色素瘤治療市場
第10章 治療用癌症疫苗研發挑戰
- 癌症疫苗臨床實驗標準
- 有效癌症疫苗之開發
- 具非侵入式經由之疫苗開發
- 由Dendreon之Provenge開發獲得之教訓
第11章 治療用癌症疫苗產品線
第12章 治療用癌症疫苗市場影響
第13章 參考資訊
Abstract
In 2010, the therapeutic cancer vaccine market witnessed several key
milestones. Dendreon' s Provenge (sipuleucel-T) became the first product to
reach the market; gaining long-awaited FDA approval for metastatic
hormone-refractory prostate cancer. The Cancer Research Institute (CRI) and
the Cancer Immunotherapy Consortium (CIC) also proposed much needed criteria
to standardize vaccine clinical trials.
Although the major milestones attained in the clinical development of
therapeutic cancer vaccines has brought hope and guidance for investors, the
market is in its commercial infancy. According to Arrowhead' s new publication:
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future
Market Impact, numerous challenges must be overcome to create optimal
vaccines on an economical scale. Stakeholders can learn from Provenge' s
developmental pathway to maximize success in this potentially lucrative market.
With over 1.3 million people having been diagnosed with colorectal cancer,
breast cancer, lung cancer, prostate cancer, pancreatic cancer or melanoma
across the seven major markets in 2010, coupled with unsatisfactory survival
rates; vaccines could hold the ability to transform the management of cancer.
This in-depth report provides:
- An identification and analysis of the major challenges within therapeutic
cancer vaccine R&D including clinical trial standardization recommendations ,
designing optimal vaccines and the lessons learnt from Provenge' s development
pathway
- Clinical and commercial analysis of key Phase III oncology vaccine
candidates
- An overview and analysis of the current markets for the treatment of
various cancers
- Insight from key opinion leaders (KOLs) on the future applicability of
therapeutic vaccines for the treatment of cancer
- Sales growth rates to 2020 for key products in development
Report highlights
Traditional cancer clinical trial endpoints are not always applicable in the
assessment of cancer vaccines. Lengthy trials allowing full data maturation of
measuring immune response is limiting market entry. R&D must establish an
effective and consistent way to assess vaccines.
Arrowhead has identified almost 400 clinical trials investigating therapeutic
oncology vaccines. Whole-cell vaccines are the most popular design in
late-stage development. Arrowhead anticipates a wave of products to reach the
market over the coming decade.
The market is set to become highly competitive, especially within the lung
cancer and melanoma sectors. By 2020 the market could be worth $8 billion. Top
revenue earning candidates include GSK' s MAGE-ASCI-A3, Merck/Oncothyreon' s
Stimuvax (BLP25), NovaRX' s Lucanix and Lorus Therapeutics/Zor Pharma' s
Virulizin.
Key questions answered by this report
- How can therapeutic cancer vaccine clinical trials be optimized to aid
regulatory approval and commercial success?
- What lessons can stakeholders learn from Provenge' s developmental and
commercial pathway?
- What is the optimal design of a therapeutic cancer vaccine?
- What candidates are in the current therapeutic cancer vaccine pipeline?
- What are the key pipeline therapeutic cancer vaccine candidates in
late-stage development?
- What are the clinical and commercial attributes of key late-stage
therapeutic cancer vaccine candidates?
- Which biopharmaceutical companies are involved in the arena?
- What revenues will therapeutic cancer vaccine products generate over the
next coming decade?
- Which cancer types will realize the greatest benefits from vaccines?
- What major challenges face the arena over the coming years; and how can
these be overcome?
- What advice do leading expert immunology/oncology vaccine developers give
to stakeholders in the arena?
- What are the greatest commercial opportunities within the future
therapeutic cancer vaccine market?
Reasons to buy this report
- Identify key therapeutic cancer vaccine candidates in late-phase
development based on sales forecasts to 2020 to maximize your products
commercial potential
- Assess opportunities and risks influencing R&D in therapeutic cancer
vaccines
- Gain an impartial perspective of strategies that can be used to enhance
new product performance in the therapeutic cancer vaccine market
- Better understand how cancer vaccines will fit into future therapeutic
regimens for cancer
Table of Contents
1 EXECUTIVE SUMMARY
- 1.1 Scope of Global Cancer Vaccine Market, 2nd Edition: the Potential
Revolution of Oncology Management
- 1.2 Methodology of Global Cancer Vaccine Market, 2nd Edition: the
Potential Revolution of Oncology Management
- 1.3 Epidemiology of Cancer in the Seven Major Markets
- 1.4 Key Challenges in Therapeutic Cancer Vaccine R&D
- 1.5 Therapeutic Cancer Vaccines Pipeline Analysis
- 1.6 Therapeutic Cancer Vaccines Market Analysis
2 THE EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF CANCER
- 2.1 Cancer Across the Globe
- 2.2 Cancer in the US
- 2.3 Cancer Survival Rates
- 2.4 The Economic Impact of Cancer
3 INTRODUCTION TO THERAPEUTIC CANCER VACCINES
- 3.1 The Immune System and Cancer
- 3.2 What are Vaccines?
- 3.3 Unmet Needs in Current Cancer Therapy
- 3.4 The Basics of Cancer Vaccines
- 3.5 Why Therapeutic Cancer Vaccines?
- 3.6 Early Efforts of Cancer Vaccines
- 3.7 Allogeneic Versus Autologous Vaccines
- 3.8 Types of Cancer Vaccines
- 3.8.1 Viral Vectors and DNA Vaccines
- 3.8.2 Antigen/Adjuvant Vaccines
- 3.8.3 Whole-Cell Cancer Vaccines
- 3.8.4 Anti-Idiotype Vaccines
- 3.8.5 Dendritic Cell Vaccines
4 VACCINES AND THE COLORECTAL CANCER THERAPEUTIC MARKET
- 4.1 Overview of Colorectal Cancer
- 4.1.1 Prognosis of Colorectal Cancer
- 4.2 Epidemiology of Colorectal Cancer in the Seven Major Markets
- 4.3 The Therapeutic Management of Colorectal Cancer
- 4.3.1 An Overview of Chemotherapy for Colorectal Cancer
- 4.3.2 Amgen' s Vectibix (panitumumab)
- 4.3.3 Roche' s Avastin (bevacizumab)
- 4.3.4 Clinical Analysis of Arrowhead' s Leading Brand Product in the
Colorectal Cancer Market: ImClone/Bristol-Myers Squibb/Merck KgaA' s Erbitux
(cetuximab)
- 4.4 Revenue Review of Colorectal Cancer Branded Products
- 4.5 Unmet Needs in the Colorectal Cancer Market
- 4.6 Therapeutic Colorectal Cancer Vaccine Pipeline Analysis
- 4.6.1 Vaccinogen' s Oncovax (oncovax-o)
- 4.7 Colorectal Cancer Market Commentary
- 4.7.1 Financial Forecast of Therapeutic Colorectal Cancer Vaccines
5 VACCINES AND THE PROSTATE CANCER THERAPEUTIC MARKET
- 5.1 Overview of Prostate Cancer
- 5.1.1 Prognosis of Prostate Cancer
- 5.2 Epidemiology of Prostate Cancer in the Seven Major Markets
- 5.3 The Therapeutic Management of Prostate Cancer
- 5.3.1 An Overview of Chemotherapy for Prostate Cancer
- 5.3.2 Sanofi-Aventis' Taxotere (docetaxol)
- 5.3.3 Clinical Analysis of Arrowhead' s Leading Brand Product in the
Prostate Cancer Market: Dendreon' s Provenege (spiuleucel-t)
- 5.4 Revenue Review of Prostate Cancer Branded Products
- 5.5 Unmet Needs in the Prostate Cancer Market
- 5.6 Therapeutic Prostate Cancer Vaccine Pipeline Analysis
- 5.6.1 Bavarian Nordic/NCI' s Prostvac
- 5.6.2 Northwest Biotherapeutic' s DCVax (dcax- prostate)
- 5.7 Prostate Cancer Therapeutics Market Commentary
- 5.7.1 Financial Forecast of Therapeutic Prostate Cancer Vaccines
6 VACCINES AND THE LUNG CANCER THERAPEUTIC MARKET
- 6.1 Lung Cancer Overview
- 6.1.1 Prognosis of Lung Cancer
- 6.2 Epidemiology of Lung Cancer in the Seven Major Markets
- 6.3 The Therapeutic Management of Lung Cancer
- 6.3.1 An Overview of Chemotherapy for Lung Cancer
- 6.3.2 Roche' s Avastin (bevacizumab)
- 6.3.3 AstraZeneca' s Iressa (gefitinib)
- 6.3.4 Clinical Analysis of Arrowhead' s Leading Brand in the Lung
Cancer Market: Roche' s Tarceva (erlotinib)
- 6.4 Revenue Review of Lung Cancer Branded Products
- 6.5 Unmet Needs in the Lung Cancer Market
- 6.6 Therapeutic Lung Cancer Vaccines Pipeline Analysis
- 6.6.1 Nova Rx' s Lucanix
- 6.6.2 Transgene/Novartis' TG4010 (mva-muc-il2)
- 6.6.3 GlaxoSmithKline' s MAGE-A3-ASCI (GSK1572932A)
- 6.6.4 Merck/Oncothyreon' s Stimuvax (BLP25)
- 6.7 LUNG CANCER THERAPEUTICS MARKET COMMENTARY
- 6.7.1 Financial Forecast of Therapeutic Lung Cancer Vaccines
7 VACCINES AND THE BREAST CANCER MARKET
- 7.1 Breast Cancer Overview
- 7.1.1 Prognosis of Breast Cancer
- 7.2 Epidemiology of Breast Cancer in the Seven Major Markets
- 7.3 The Therapeutic Management of Breast Cancer
- 7.3.1 An Overview of Chemotherapy for Breast Cancer
- 7.3.2 GlaxoSmithKline' s Tykerb/Tyverb (lapatinib)
- 7.3.3 Clinical Analysis of Arrowhead' s Leading Brand in the Breast
Cancer Market: Roche' s Herceptin (trastuzumab)
- 7.4 Revenue Review of Breast Cancer Branded Products
- 7.5 Unmet Needs in the Breast Cancer Market
- 7.6 Therapeutic Breast Cancer Vaccine Pipeline Analysis
- 7.7 Breast Cancer Therapeutics Market Commentary
- 7.7.1 Financial Forecast of Breast Cancer Therapeutic Vaccines
8 VACCINES AND THE PANCREATIC CANCER MARKET
- 8.1 Pancreatic Cancer Overview
- 8.1.1 Prognosis of Pancreatic Cancer
- 8.2 Epidemiology of Pancreatic Cancer in the Seven Major Markets
- 8.3 The Therapeutic Management of Pancreatic Cancer
- 8.3.1 An Overview of Chemotherapy for Pancreatic Cancer
- 8.3.2 Roche' s Tarceva (erlotinib)
- 8.3.3 Clinical Analysis of Arrowhead' s Leading Brand Product in the
Pancreatic Cancer Market: Eli-Lilly' s Gemzar (gemcitabine)
- 8.4 Revenue Review of Pancreatic Cancer Branded Products
- 8.5 Unmet Needs in the Pancreatic Cancer Market
- 8.6 Therapeutic Pancreatic Cancer Vaccine Pipeline Analysis
- 8.6.1 Kael/GemVax' s GV1001
- 8.6.2 Lorus Therapeutic/Zor Pharma' s Virulizin
- 8.7 Pancreatic Cancer Therapeutic Market Commentary
- 8.7.1 Financial Forecast of Pancreatic Cancer Therapeutic Vaccines
9 VACCINES AND THE MELANOMA MARKET
- 9.1 Melanoma Overview
- 9.1.1 Prognosis of Melanoma
- 9.2 Epidemiology of Melanoma in the Seven Major Markets
- 9.3 The Therapeutic Management of Melanoma
- 9.3.1 An Overview of Chemotherapy for Melanoma
- 9.3.2 Merck/Schering-Plough' s Intron-A (interferon-Alfa 2b)
- 9.3.3 Clinical Analysis of Arrowhead' s Leading Brand in the Melanoma
Market: Novartis' Proleukin (aldesleukin)
- 9.4 Revenue Review of Melanoma Branded Products
- 9.5 Unmet Needs in the Melanoma Market
- 9.6 Therapeutic Melanoma Vaccine Pipeline Analysis
- 9.6.1 AVAX Tech' s M-Vax (autologous cell vaccine)
- 9.6.2 Goshen Health System/NCI' s Gp100 Antigen
- 9.6.3 BioVex' s OncoVEX (oncovex gm-csf)
- 9.6.4 Antigenic' s Oncophage (vitespen)
- 9.7 Melanoma Therapeutics Market Commentary
- 9.7.1 Financial Forecast of Melanoma Therapeutic Vaccines
10 KEY ISSUES IN THERAPEUTIC CANCER VACCINE RESEARCH AND DEVELOPMENT (R&D)
- 10.1 Standardization of Cancer Vaccine Clinical Trials
- 10.1.1 FDA Proposals of Standardizing Therapeutic Cancer Vaccine
Clinical Trials
- 10.1.2 CRI and CIC Proposals of Standardizing Therapeutic Cancer
Vaccine Clinical Trials
- 10.1.3 Autologous Therapeutic Cancer Vaccine Clinical Trial Designs
- 10.2 Creating Highly Effective Therapeutic Cancer Vaccines
- 10.2.1 Vaccine Designs: Antigen Versus Adjuvant s
- 10.2.2 Optimal Disease Stage
- 10.2.3 Concomitant Therapies
- 10.3 Development of Vaccines with Non-invasive Delivery Routes
- 10.4 Lessons to be Learnt from Dendreon' s Provenge Development
11 THERAPEUTIC CANCER VACCINES PIPELINE WATCH
- 11.1 Introduction to the Therapeutic Cancer Vaccine Pipeline
- 11.1.1 Accentia/BioVest' s BioVaxID
- 11.1.2 TVAX Biomedicals' TVAX (Tvax-Brain-1)
- 11.2 Development Status Updates of Phase III Candidate Therapeutic
Cancer Vaccines
12 THERAPEUTIC CANCER VACCINES MARKET IMPACT
- 12.1 Therapeutic Cancer Vaccine Potential Promise
- 12.2 SWOT Analysis of the Therapeutic Cancer Vaccine Market, 2010
- 12.3 Financial Forecast of the Therapeutic Cancer Vaccine Market
13 BIBLIOGRAPHY
LIST OF TABLES
- Table 1: Colorectal, Prostate, Lung, Breast, Pancreatic and Melanoma
Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
- Table 2: Current Late-Stage Therapeutic Cancer Vaccine Pipeline, November
2010
- Table 3: Worldwide Incidence of Cancer by Geographic Region, 2008
- Table 4: Worldwide Incidence and Deaths Rates by Leading Cancer Type, 2008
- Table 5: Worldwide Number of Cancer Cases for Both Males and Females
Combined, 2008
- Table 6: Estimated Newly Diagnosed Cases and Death Rates in the US by
Cancer Type, 2010
- Table 7: Five-Year Survival Rates for Select Cancers by Stage at
Diagnosis, US 2005
- Table 8: The Economic Impact of Cancer in the US, 2010
- Table 9: Colorectal Cancer Diagnosis and Five-Year Survival Rate by
Disease Stage
- Table 10: Crude Incidence Rate of Colorectal Cancer by Gender in the Seven
Major Markets, 2010
- Table 11: Colorectal Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Table 12: Therapeutics Used in Colorectal Cancer
- Table 13: Worldwide Leading Colorectal Cancer Branded Product Revenues ($
millions) 2007- H1 2010
- Table 14: Late-Stage and Phase II Therapeutic Colorectal Cancer Vaccines
Pipeline, November 2010
- Table 15: Colorectal Cancer Therapeutic Vaccines Revenue Forecast
2015-2020 ($ millions)
- Table 16: Prostate Cancer Diagnosis and Five-Year Survival Rate by Disease
Stage
- Table 17: Crude Incidence Rate of Prostate Cancer for Males in the Seven
Major Markets, 2010
- Table 18: Prostate Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Table 19: Therapeutics Used in Prostate Cancer
- Table 20: Worldwide Leading Prostate Cancer Branded Product Revenues ($
millions) 2007- H1 2010
- Table 21: Late-Stage and Phase II Therapeutic Prostate Cancer Vaccine
Pipeline, November 2010
- Table 22: Prostate Cancer Therapeutic Vaccines Revenue Forecast 2010-2020
($ millions)
- Table 23: Lung Cancer Diagnosis and Five-Year Survival Rate by Disease
Stage
- Table 24: Crude Incidence Rate of Lung Cancer by Gender (per 100,000) in
the Seven Major Markets, 2010
- Table 25: Lung Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Table 26: Therapeutics Used in Lung Cancer
- Table 27: Worldwide Leading Lung Cancer Branded Product Revenues ($
millions) 2007-2010 H1
- Table 28: Late-Stage and Phase II Therapeutic Lung Cancer Vaccines
Pipeline, November 2010
- Table 29: Lung Cancer Therapeutic Vaccines Revenue Forecast 2010-2020 ($
millions)
- Table 30: Breast Cancer Diagnosis and Five-Year Survival Rate by Disease
Stage
- Table 31: Crude Incidence Rate of Breast Cancer for Females in the Seven
Major Markets, 2010
- Table 32: Breast Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Table 33: Therapeutics Used in Breast Cancer
- Table 34: Worldwide Leading Breast Cancer Branded Product Revenues ($
millions) 2007-2010 H1
- Table 35: Late-Stage and Phase II Therapeutic Breast Cancer Vaccines
Pipeline, November 2010
- Table 36: Pancreatic Cancer Diagnosis and Five-Year Survival Rate by
Disease Stage
- Table 37: Crude Incidence Rate of Pancreatic Cancer by Gender in the Seven
Major Markets, 2010
- Table 38: Pancreatic Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Table 39: Therapeutics Used in Pancreatic Cancer
- Table 40: Worldwide Leading Pancreatic Cancer Branded Product Revenues ($
millions) 2007-H1 2010
- Table 41: Late-Stage and Phase II Therapeutic Pancreatic Cancer Vaccines
Pipeline, Novemeber 2010
- Table 42: Pancreatic Cancer Therapeutic Vaccines Revenue Forecast
2015-2020 ($ millions)
- Table 43: Melanoma Cancer Diagnosis and Five-Year Survival Rate by Disease
Stage
- Table 44: Crude Incidence Rate of Melanoma by Gender in the Seven Major
Markets, 2010
- Table 45: Melanoma Incidence Forecast in the Seven Major Markets, 2008-2020
- Table 46: Therapeutics Used in Melanoma
- Table 47: Worldwide Leading Melanoma Branded Product Revenues ($ millions)
2007-H1 2010
- Table 48: Late-Stage and Phase II Therapeutic Melanoma Vaccines Pipeline,
November 2010
- Table 49: Melanoma Therapeutic Vaccines Revenue Forecast 2010-2020 ($
millions)
- Table 50: FDA' s Considerations for Therapeutic Cancer Vaccine Clinical
Trials
- Table 51: Challenges and Recommendations for Assessment of Cancer
Immunotherapies
- Table 52: The Relative Advantages of Different Therapeutic Cancer Vaccine
Designs
- Table 53: Current Late Stage and Phase II Therapeutic Cancer Vaccines
Pipeline, November 2010
- Table 54: Development Status Updates of Selected Phase III Therapeutic
Cancer Vaccines
- Table 55: Therapeutic Cancer Vaccines Revenue Forecast 2010-2020 ($
millions)
LIST OF FIGURES
- Figure 1: Colorectal, Prostate, Lung, Breast, Pancreatic and Melanoma
Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
- Figure 2: Cancer Incidence Forecast in the Seven Major Markets, 2010 and
2020
- Figure 3: Key Challenges in Therapeutic Cancer Vaccine R&D
- Figure 4: The Late-Stage Therapeutic Cancer Vaccine Pipeline by the
Number of Candidates of Different Vaccine Type Design, November 2010
- Figure 5: Comparison of the Value of the Therapeutic Cancer Vaccine
Market, 2010 and 2020
- Figure 6: Cancer Incidence Worldwide by Geographic Region, 2008
- Figure 7: Worldwide Number of Cancer Cases for Males and Females
Combined, 2008
- Figure 8: Schematic Diagram of the Production of DNA/Viral Vector Vaccines
- Figure 9: Schematic Diagram of Antigen/Adjuvant Vaccines Mode of Action
- Figure 10: Schematic Diagram of Whole-Cell Tumor Vaccine Production
- Figure 11: Schematic Diagram of Anti-Idiotype Vaccine Production
- Figure 12: Schematic Diagram of Dendritic Cell Cancer Vaccine Production
- Figure 13: The Anatomy of the Human Digestive System
- Figure 14: Colorectal Cancer Incidence Forecast in the Seven Major
Markets, 2008-2020
- Figure 15: OncoVax' s Treatment Schedule
- Figure 16: The Anatomy of the Male Reproductive System
- Figure 17: Prostate Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Figure 18: The Anatomy of the Human Respiratory System
- Figure 19: Lung Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Figure 20: The Anatomy of the Human Breast
- Figure 21: Breast Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
- Figure 22: The Anatomy of the Human Pancreas
- Figure 23: Pancreatic Cancer Incidence Forecast in the Seven Major
Markets, 2008-2020
- Figure 24: The Anatomy of Human Skin
- Figure 25: Melanoma Incidence Forecast in the Seven Major Markets,
2008-2020
- Figure 26: The Current Therapeutic Cancer Vaccine Pipeline by the Number
of Candidates by Vaccine Type, November 2010
- Figure 27: SWOT Analysis of the Therapeutic Cancer Vaccine Market, 2010
- Figure 28: Therapeutic Cancer Vaccines Revenue Forecast 2010-2020 ($
millions)
- Figure 29: Total Therapeutic Cancer Vaccine Market Revenue Forecast
2010-2020 ($ millions)
|
 |
